Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

NYSE:PFE - Post by User

Pfizer Inc

Bullboard Posts

Post by leonclarence830on May 13, 2013 11:25am

381 Views

Post# 21385343

30% of the people that read this message succeed

InfuSystem Holdings the leading provider of infusion pumps and
associated clinical services, announced today that its Board of
Directors has authorized a share repurchase program of up to $2
million of the Company's outstanding common shares. The repurchase
program will be funded by the Company's available cash balance. The
Board of Directors believes that a share repurchase program would be
in the best interests of the Company and its shareholders, and that it
will not impact the Company's ability to execute its growth plans.